Medlab Clinical on schedule with medicinal cannabis cancer trial

Medlab Clinical Ltd (ASX:MDC) is on schedule with recruitment for the clinical trial of its cannabis-based cancer medicine, NanaBis™, at Royal North Shore Hospital in Sydney.

The trial will test the safety, efficacy and dose tolerance in cancer patients with both managed and unmanaged pain.

READ: Medlab Clinical begins trial of cannabis-based cancer pain management medicine

The recruitment update coincides with separate positive feedback received from doctors who have been prescribing the medicine.

Feedback from some doctors is that it is proving effective in decreasing reliance on opioids and in its speed of action, aided by delivery through Medlab’s nano-particle spray, NanoCelle™

Under the Therapeutic Goods Administration’s (TGA) Special Access Scheme, Medlab has approval to supply NanaBis™ to medical practitioners for use with patients suffering cancer pain.

NanaBis™ is one of two developed formulas

Medlab has developed two cannabis-based medicines which have differing cannabis formulations, NanaBis™

... read more at: http://www.proactiveinvestors.com.au/companies/news/200313/medlab-clinical-on-schedule-with-medicinal-cannabis-cancer-trial-200313.html

Leave a Reply

Your email address will not be published. Required fields are marked *